Design Therapeutics Reports Q2 2023 Results, Pipeline Progress with DT-216 and DT-168

Design Therapeutics, Inc.

2023-Q2 EPS reported -$0.70

Initial Phase 1 data for DT-216 in Friedreich Ataxia showed significant dose-related FXN mRNA increase in skeletal muscle (p<0.05)
DT-216 Phase 1 MAD trial resumed in H2 2024 with improved formulation, data expected H1 2025
IND submission for DT-168 for Fuchs Endothelial Corneal Dystrophy on track for H2 2023
Cash and securities of $303.1M as of June 30, 2023, expected to fund operations through 2026
Net loss of $19.9M for Q2 2023; R&D expenses $17.1M, G&A $5.5M

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Design Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the quarter ended June 30, 2023..

Period: the quarter ended June 30, 2023
Net income: Net loss was $19.9 million for the quarter ended June 30, 2023.
Result: reported results

Exact text from the filing

Net loss was $19.9 million for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-042392

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.